Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel
Clinical trial NCT05582538 · RECRUITING
Trial details
- NCT number
- NCT05582538
- Sponsor
- IFOM ETS - The AIRC Institute of Molecular Oncology
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-15
- Primary completion
- 2027-12-01
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.